Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Clinical-trials-phase-iii symbols : AMGN save search
BLINCYTO® (BLINATUMOMAB) ADDED TO CONSOLIDATION CHEMOTHERAPY SIGNIFICANTLY IMPROVES SURVIVAL IN ADULT PATIENTS WITH MEASURABLE RESIDUAL DISEASE-NEGATIVE B-LINEAGE ACUTE LYMPHOBLASTIC LEUKEMIA (B-ALL)
Published: 2022-12-13 (Crawled : 01:00) - biospace.com/
BGNE | $142.065 2.21% 100K
|
Health Technology
|
| O: 2.79%
H: 1.42%
C: -0.92%
AMGN | News | $274.065 0.19% 570K
|
Health Technology
|
| O: 1.9%
H: 0.23%
C: -3.46%
blincyto leukemia
Entera Bio Announces FDA Agreement for a Single Phase 3 Clinical Trial to Support an NDA for EB613 for the Treatment of Osteoporosis- Total Hip BMD Established as Primary Endpoint -
Published: 2022-10-06 (Crawled : 12:00) - biospace.com/
ENTX | $2.21 -0.45% 19K
|
Health Technology
|
| O: 7.62%
H: 0.0%
C: -7.08%
AMGN | News | $274.065 0.19% 570K
|
Health Technology
|
| O: -0.56%
H: 0.27%
C: -0.68%
eb613 treatment fda trial agreement
AMGEN ANNOUNCES POSITIVE TOP-LINE RESULTS FROM PHASE 3 STUDY OF ABP 959, BIOSIMILAR CANDIDATE TO SOLIRIS® (ECULIZUMAB)
Published: 2022-08-23 (Crawled : 14:00) - biospace.com/
CCXI | News | $51.99 -0.04%
|
Health Technology
|
| O: -0.12%
H: 0.0%
C: 0.0%
BGNE | $142.065 2.21% 100K
|
Health Technology
|
| O: -0.57%
H: 1.88%
C: 0.59%
AMGN | News | $274.065 0.19% 570K
|
Health Technology
|
| O: -0.09%
H: 0.0%
C: -0.9%
soliris candidate biosimilar positive results study
AMGEN ANNOUNCES RESULTS FROM TWO OPEN LABEL EXTENSION STUDIES OF REPATHA® (EVOLOCUMAB)
Published: 2022-04-27 (Crawled : 14:00) - biospace.com/
BGNE | $142.065 2.21% 100K
|
Health Technology
|
| O: 1.64%
H: 6.35%
C: 1.76%
AMGN | News | $274.065 0.19% 570K
|
Health Technology
|
| O: -0.33%
H: 1.2%
C: -0.1%
repatha label results
AMGEN ANNOUNCES POSITIVE TOP-LINE RESULTS FROM PHASE 3 STUDY OF ABP 654, BIOSIMILAR CANDIDATE TO STELARA® (USTEKINUMAB)
Published: 2022-04-18 (Crawled : 22:00) - biospace.com/
BGNE | $142.065 2.21% 100K
|
Health Technology
|
| O: -1.9%
H: 0.12%
C: -3.78%
AMGN | News | $274.065 0.19% 570K
|
Health Technology
|
| O: -0.46%
H: 0.0%
C: 0.0%
stelara biosimilar positive results phase 3 topline
Amgen Announces Positive Top-Line Results From Otezla® (apremilast) Phase 3 DISCREET Study In Moderate To Severe Genital Psoriasis
Published: 2021-12-01 (Crawled : 22:00) - biospace.com/
BGNE | $142.065 2.21% 100K
|
Health Technology
|
| O: 3.7%
H: 3.74%
C: -0.91%
AMGN | News | $274.065 0.19% 570K
|
Health Technology
|
| O: 0.78%
H: 2.59%
C: 0.18%
psoriasis positive results phase 3 topline
Bristol Myers Squibb Presents Positive Data from Two Pivotal Phase 3 Psoriasis Studies Demonstrating Superiority of Deucravacitinib Compared to Placebo and Otezla® (apremilast)
Published: 2021-04-23 (Crawled : 18:00) - biospace.com/
BMY | $48.76 -0.47% 3.9M
|
Health Technology
|
| O: -0.03%
H: 0.95%
C: -0.44%
AMGN | News | $274.065 0.19% 570K
|
Health Technology
|
| O: -0.03%
H: 1.24%
C: 0.8%
positive phase 3 psoriasis
BeiGene Presents Interim Analysis Results of RATIONALE 303 Trial of Tislelizumab in Second- or Third-Line Non-Small Cell Lung Cancer at the AACR Annual Meeting 2021
Published: 2021-04-12 (Crawled : 20:00) - biospace.com/
BGNE | $142.065 2.21% 100K
|
Health Technology
|
| O: 0.09%
H: 0.0%
C: -4.44%
AMGN | News | $274.065 0.19% 570K
|
Health Technology
|
| O: -0.17%
H: 0.6%
C: 0.17%
lung cancer results cancer trial
Tezepelumab Is The First Biologic To Significantly Reduce Exacerbations In Broad Population Of Patients With Severe, Uncontrolled Asthma
Published: 2021-02-26 (Crawled : 15:00) - biospace.com/
AMGN | News | $274.065 0.19% 570K
|
Health Technology
|
| O: 1.23%
H: 0.0%
C: -2.34%
Gainers vs Losers
| 55% | 45% |
Top 10 Gainers
CSSE 4 | $0.3499 129.74% 150M
|
Consumer Services
CZOO | $11.04 121.24% 9.6M
|
BOF | $2.05 75.21% 78M
|
AMST | $3.2 60.0% 63M
|
Technology Services
LICN | $0.8592 53.43% 13M
|
WIMI | $1.05 44.75% 13M
|
Technology Services
TROO | $1.51 38.53% 5.6M
|
Manufacturing
MULN | News | $3.7 35.53% 6.4M
|
Information
RILY | $27.91 28.5% 8.9M
|
Finance
WHLM | $6.43 26.58% 580K
|
Commercial Services
Your saved searches
Save your searches and get alerts when important news are released.